公开(公告)号：US20240050401A1

公开(公告)日：2024-02-15

申请号：US18192234

申请日：2023-03-29

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： David Blum

IPC: A61K31/381 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38

CPC classification number: A61K31/381 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38

Abstract: Methods and compositions for treating social function disorders are disclosed. The methods involve administering compound of Formula I

公开(公告)号：US20230072389A1

公开(公告)日：2023-03-09

申请号：US17748165

申请日：2022-05-19

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D207/09

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

公开(公告)号：US20220062229A1

公开(公告)日：2022-03-03

申请号：US17223229

申请日：2021-04-06

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Hopkins ,  Kenneth Koblan ,  Antony Loebel ,  Ajay Ogirala

IPC: A61K31/381 ,  A61P25/18

Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

公开(公告)号：US11192885B2

公开(公告)日：2021-12-07

申请号：US16403698

申请日：2019-05-06

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Linghong Xie ,  Philip Glyn Jones ,  Kerry L. Spear ,  Noel Aaron Powell ,  Taleen G. Hanania ,  Vadim Alexandrov

IPC: C07D405/04 ,  C07D405/14 ,  C07D413/14 ,  C07D493/04 ,  C07D413/04

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US20210322403A1

公开(公告)日：2021-10-21

申请号：US17186439

申请日：2021-02-26

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Anthony John GIOVINAZZO ,  David Bruce HEDDEN ,  Marc L. DE SOMER ,  Nathan John BRYSON

IPC: A61K31/485 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/70 ,  A61K47/02 ,  A61P15/10 ,  A61P25/16 ,  A61K31/473 ,  A61K47/10

Abstract: The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

公开(公告)号：US20210315882A1

公开(公告)日：2021-10-14

申请号：US17344314

申请日：2021-06-10

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Thierry BILBAULT ,  Bradford Armando NAVIA ,  Charles Warren OLANOW

IPC: A61K31/473 ,  A61K9/00 ,  A61P25/16

Abstract: Methods of treating a patient having Parkinson's disease, including treating “OFF” episodes and improving motor function, by administering apomorphine or a pharmaceutically acceptable salt thereof are disclosed herein. Supratherapeutic doses of apomorphine may be used. Apomorphine therapy may be used in place of levodopa therapy, or apomorphine may be used to supplant or augment the first levodopa dose of the day. Apomorphine therapy may involve administration of two consecutive apomorphine doses at least 2 hours apart.

公开(公告)号：US11066380B2

公开(公告)日：2021-07-20

申请号：US16817749

申请日：2020-03-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nandkumar Nivritti Bhogle ,  Takahiko Hashizuka ,  Robert Joseph Prytko ,  John R. Snoonian ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D311/76

Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

公开(公告)号：US10894033B2

公开(公告)日：2021-01-19

申请号：US16791118

申请日：2020-02-14

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Liming Shao ,  John Emmerson Campbell ,  Michael Charles Hewitt ,  Una Campbell ,  Taleen G. Hanania

IPC: A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  A61K45/06 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  C07D333/78

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US20210002051A1

公开(公告)日：2021-01-07

申请号：US17029468

申请日：2020-09-23

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Julie A. CARDIN ,  Edward Emmett CHAPDELAINE ,  Steven A. RAU

IPC: B65D75/58 ,  B65B9/00 ,  B65D75/50 ,  B65D75/30 ,  B65D75/52 ,  B65B7/02 ,  B65B9/02 ,  B65B61/00 ,  B65B61/06

Abstract: Embodiments include a package for containing and dispensing a product. The package includes first and second layers; a product seal zone where the first layer is joined to the second layer, the product seal zone having an inner perimeter that defines an unsealed pouch area for containing the product and an outer perimeter; and a header zone adjacent to the outer perimeter of the product seal zone. The header zone includes a first tab; a second tab; a first tab-cut in the first layer within an unsealed portion of the header zone; and a second tab-cut in the second layer within the unsealed portion of the header zone. Other embodiments are also included herein.

公开(公告)号：US10780074B2

公开(公告)日：2020-09-22

申请号：US16051863

申请日：2018-08-01

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Carrie A. Bowen ,  Douglas F. Burdi ,  Michele L. R. Heffernan ,  Lee W. Herman ,  Linghong Xie

IPC: C07D413/04 ,  C07D417/04 ,  C07D405/04 ,  A61K31/352 ,  A61P25/28 ,  A61P25/24 ,  A61P25/08 ,  A61P25/16 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/42 ,  A61K31/427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/506

Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.